Prescription Required
Description
MYRBETRIQ (mirabregon) Indications
Myrbetriq is a prescription medication indicated for the treatment of overactive bladder (OAB), a condition that occurs when you cannot control your bladder contractions. OAB is characterized by symptoms of urinary frequency, urinary urgency, and urinary incontinence (leakage). This medication works by relaxing the muscles of the urinary bladder, reducing bladder spasms, and improving urinary control.
MYRBETRIQ (mirabregon) Dosage and Administration
- The recommended starting dose is 25 mg once daily, alone or in combination with solifenacin succinate 5 mg, once daily.
- Based on individual efficacy and tolerability, the dose may be increased to 50 mg once daily, alone or in combination with solifenacin succinate 5 mg, once daily.
Myrbetriq should be taken with water, swallowed whole, and should not be chewed, divided, or crushed.
The dosage of Myrbetriq should be determined by your doctor and tailored to your individual medical condition and response to treatment.
Side Effects of MYRBETRIQ (mirabregon)
The most common side effects of Myrbetriq when given alone were:
- Elevated blood pressure
- Nasopharyngitis
- Urinary tract infection
- Headache
The most common side effects of Myrbetriq when given in combination with solfenacin succinate 5mg were:
- Dry mouth
- Urinary tract infection
- Constipation
- Rapid heart rate
This is not a complete list of side effects of Myrbetriq. Consult your doctor if you experience any uncommon side effects.
SERIOUS SIDE EFFECTS
If you develop any serious side effects, including burning/painful urination, contact your doctor right away.
Since Myrbetriq has the potential to raise your blood pressure, check your blood pressure regularly and tell your doctor if the results are high.
ALLERGIC REACTIONS
Although a serious allergic reaction to this drug is rare, you should discontinueMyrbetriq and seek immediate medical attention if you develop any symptoms of a serious allergic reaction, including:
- Hives or rash
- Itching/swelling (especially of the face/tongue/throat)
- Difficulty breathing
- Severe dizziness
MYRBETRIQ (mirabregon) Warnings and Precautions
Myrbetriq can increase blood pressure. It is not recommended for use  in individuals who have severe uncontrolled hypertension (defined as systolic blood pressure [the top number of the blood pressure reading] greater than or equal to 180 mm Hg and/or diastolic blood pressure [the bottom number of the blood pressure reading] greater than or equal to 110 mm Hg).
Urinary retention has been recorded in individuals on Myrbetriq who have a bladder outlet obstruction or who are receiving a muscarinic antagonist  (also known as an anticholinergic; for example, atropine, scopolamine, ipratropium bromide) for the treatment of OAB.
Angioedema (swelling in the deep layers of the skin) of the face, lips, tongue, and/or throat has been reported with Myrbetriq.  Angioedema developed in some individuals after the first dosage. Cases of angioedema have been reported to occur hours after the first dose or after multiple doses. If involvement of the tongue, hypopharynx, or larynx occurs, Myrbetriq should be discontinued immediately and appropriate therapy and/or measures to maintain a patent airway should be started.
MYRBETRIQ (mirabregon) Form and Strengths
You can order Myrbetriq (mirabregon) medication in the following form and strengths:
- Myrbetriq extended-release tablet
- 25 mg
- 50 mg
- Mirabregon extended-release tablet
- 25mg
- 50mg
Frequently Asked Questions
Are there any drug interactions I should be aware of while taking Myrbetriq?
Myrbetriq has the potential to slow down the removal of certain medications from your body, which may affect how they work. Examples of affected drugs include flecainide, propafenone, and thioridazine.
Myrbetriq is also known to interact with digoxin and warfarin. It is important to notify your doctor if you are taking these or any other medications prior to starting Myrbetriq.
Do I have to take Myrbetriq daily?
Take the Myrbetriq extended-release tablet as directed by your healthcare provider.
REFERENCES
https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202611s011lbl.pdf
